Study outcomes
The assessed outcomes in this meta-analysis comprised clinical improvement of AR symptoms, use of rescue medication, rhinoconjunctivitis-related quality of life and the occurrence of adverse events. Studies, that assessed the safety and efficacy of omalizumab regarding the aforementioned outcomes, were included in the systematic review and meta-analysis regardless of the type and number of outcomes.